Login
$MNPR
$71.97 -$0.03 (0.04%) Live

Company Executives

Officer Age In this role 2025 pay Source
Chandler D. Robinson Also a director
Chief Executive Officer, Director
42 Not stated $10,637,821
Quan A. Vu
Chief Financial Officer, Secretary and Treasurer
54 Not stated $2,101,314
Andrew J. Cittadine
Chief Operating Officer
54 Since 2021
5 years
$4,706,431
Susan Rodriguez
CCSO
Title from the Form 4 dated Mar 2, 2026
Not stated Since 2026
this year
Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
6
serving now
Independent
4 of 6
stated in the proxy
Average tenure
7.4 years
from year joined
CEO also chairs the board
No
Christopher M. Starr
Director Age On board Independent Committees Other public boards 2025 pay Source
Christopher M. Starr
73 2014
12 years
Independent
Plan Administrator Committee
Thiogenesis Therapeutics Corp. Not stated
Chandler D. Robinson
42 2014
12 years
Not independent None stated None stated Paid as CEO
Raymond W. Anderson
84 2017
9 years
Independent
Audit Committee · Chair Compensation Committee · Chair Corporate Governance and Nominating Committee Plan Administrator Committee
None stated $409,224
Kim R. Tsuchimoto
63 2023
3 years
Not independent None stated Thiogenesis Therapeutics Corp. $389,937
Lavina Talukdar
52 2025
1 year
Independent
Audit Committee Compensation Committee Corporate Governance and Nominating Committee Plan Administrator Committee
None stated $225,331
Arthur Klausner Leaving at the meeting
Not stated Not stated Independent
Audit Committee
None stated $401,224
Nominated to join at the meeting
Not on the board yet; they join only if elected.

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

1 disclosed in the proxy filed Apr 30, 2026
Tactic Pharma LLC
Chandler D. Robinson, Monopar's Chief Executive Officer and a member of the Board of Directors, is a minority owner and non-controlling Managing Member of Tactic Pharma
$35 million
2025

Share repurchase: the Company repurchased 550,229 shares of its Common Stock from Tactic Pharma at the public offering price less underwriting discounts and commissions, using $35 million of September 2025 offering proceeds.

With Monopar Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support